Acura Pharmaceuticals Inc said the U.S. Food and Drug Administration agreed to review the results of a failed mid-stage trial of a painkiller made with the company's technology designed to deter abuse. Results from the mid-stage trial showed in August that Acura's tablet, being tested for potential abuse by snorting, did not significantly reduce likability among abusers. Acura said on Monday that FDA agreed to provide a definitive response regarding the suitability of the trial to be considered in an approval application review. Acura shares were trading at $2.08 before the bell.
Source: REUTERS
Swirl >>
VC Funding And Acquisitions Of Israeli Startups In November - FORBES
Delta Pilot Sends Actress Handwritten Note - ABC
Who If Not Me Why One Ukrainian Activist Is Protesting - THE ATLANTIC
Fergies Yearbook Photo Is Everything According To Miley Cyrus - HUFFINGTON
Microsoft disrupts ZeroAccess botnet - BBC
Love Actuallyem Is the Least Romantic Film of All Time - THE ATLANTIC
A Turkish War of Religion Kurdish Activists Sense a Conspiracy - TIME
Doubleheader Shields Brooks on Acela eavesdropping and World Series picks - PBS NEWSHOUR
No comments:
Post a Comment